Literature DB >> 11853948

SAS and SPLUS programs to perform Cox regression without convergence problems.

Georg Heinze1, Meinhard Ploner.   

Abstract

When analyzing survival data, the parameter estimates and consequently the relative risk estimates of a Cox model sometimes do not converge to finite values. This phenomenon is due to special conditions in a data set and is known as 'monotone likelihood'. Statistical software packages for Cox regression using the maximum likelihood method cannot appropriately deal with this problem. A new procedure to solve the problem has been proposed by G. Heinze, M. Schemper, A solution to the problem of monotone likelihood in Cox regression, Biometrics 57 (2001). It has been shown that unlike the standard maximum likelihood method, this method always leads to finite parameter estimates. We developed a SAS macro and an SPLUS library to make this method available from within one of these widely used statistical software packages. Our programs are also capable of performing interval estimation based on profile penalized log likelihood (PPL) and of plotting the PPL function as was suggested by G. Heinze, M. Schemper, A solution to the problem of monotone likelihood in Cox regression, Biometrics 57 (2001).

Entities:  

Mesh:

Year:  2002        PMID: 11853948     DOI: 10.1016/s0169-2607(01)00149-3

Source DB:  PubMed          Journal:  Comput Methods Programs Biomed        ISSN: 0169-2607            Impact factor:   5.428


  7 in total

1.  Assessing covariate effects using Jeffreys-type prior in the Cox model in the presence of a monotone partial likelihood.

Authors:  Jing Wu; Mário de Castro; Elizabeth D Schifano; Ming-Hui Chen
Journal:  J Stat Theory Pract       Date:  2017-04-12

2.  Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study.

Authors:  Hussam Al-Kateb; Andrew P Boright; Lucia Mirea; Xinlei Xie; Rinku Sutradhar; Alireza Mowjoodi; Bhupinder Bharaj; Michelle Liu; Jean M Bucksa; Valerie L Arends; Michael W Steffes; Patricia A Cleary; Wanjie Sun; John M Lachin; Paul S Thorner; Michael Ho; Amy Jayne McKnight; A Peter Maxwell; David A Savage; Kenneth K Kidd; Judith R Kidd; William C Speed; Trevor J Orchard; Rachel G Miller; Lei Sun; Shelley B Bull; Andrew D Paterson
Journal:  Diabetes       Date:  2007-10-03       Impact factor: 9.461

3.  A statistical note on analyzing and interpreting individual-level epidemiological data.

Authors:  Daisuke Yoneoka; Eiko Saito
Journal:  J Epidemiol       Date:  2015       Impact factor: 3.211

4.  The project MinE databrowser: bringing large-scale whole-genome sequencing in ALS to researchers and the public.

Authors:  Rick A A van der Spek; Wouter van Rheenen; Sara L Pulit; Kevin P Kenna; Leonard H van den Berg; Jan H Veldink
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2019-08       Impact factor: 4.092

5.  Assessment of Sodium MRI at 7 Tesla as Predictor of Therapy Response and Survival in Glioblastoma Patients.

Authors:  Daniel Paech; Sebastian Regnery; Tanja Platt; Nicolas G R Behl; Nina Weckesser; Paul Windisch; Katerina Deike-Hofmann; Wolfgang Wick; Martin Bendszus; Stefan Rieken; Laila König; Mark E Ladd; Heinz-Peter Schlemmer; Jürgen Debus; Sebastian Adeberg
Journal:  Front Neurosci       Date:  2021-12-01       Impact factor: 4.677

6.  Estimating multiple time-fixed treatment effects using a semi-Bayes semiparametric marginal structural Cox proportional hazards regression model.

Authors:  Stephen R Cole; Jessie K Edwards; Daniel Westreich; Catherine R Lesko; Bryan Lau; Michael J Mugavero; W Christopher Mathews; Joseph J Eron; Sander Greenland
Journal:  Biom J       Date:  2017-10-27       Impact factor: 2.207

7.  To handle the inflation of odds ratios in a retrospective study with a profile penalized log-likelihood approach.

Authors:  I-Shiang Tzeng
Journal:  J Clin Lab Anal       Date:  2021-05-27       Impact factor: 2.352

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.